Leading U.S. cardiology organizations on March 13, 2026, released updated guidelines calling for earlier cholesterol screening and more aggressive treatment to curb lifelong exposure to harmful lipids, a shift experts say could dramatically reduce heart attacks, strokes and other cardiovascular events.

The "2026 American Heart Association Journals Guideline on the Management of Dyslipidemia," published in Circulation and the Journal of the American College of Cardiology, retires the 2018 blood cholesterol guideline. Endorsed by 11 professional societies, it emphasizes primordial and primary prevention through lifetime lipid management, including universal lipoprotein(a) testing, a new risk calculator and lower LDL cholesterol targets.

Pictured: A man is holding a heart-shaped balloon.

A core message: Start assessing and addressing elevated cholesterol as early as age 30, rather than waiting until 40. "Treat dyslipidemia earlier to reduce lifelong risk of prolonged exposure to atherogenic lipoproteins," the guideline states. Lower LDL for longer yields greater protection against future heart attack and stroke, akin to sustained blood pressure control.

The guideline promotes healthy lifestyle habits first—maintaining healthy weight, regular physical activity, tobacco avoidance, quality sleep and, when needed, earlier addition of lipid-lowering medications. For many, this means considering statins or other therapies sooner if LDL remains high after lifestyle optimization.

Key changes include adopting the PREVENT-ASCVD risk calculator for adults aged 30-79, replacing older tools that overestimated risk by 40-50%. The PREVENT equations provide more accurate 10-year estimates, categorizing risk as low (<3%), borderline (3-5%), intermediate (5-10%) or high (≥10%).

LDL-C and non-HDL-C goals return prominently. To prevent a first heart attack or stroke:
- Borderline or intermediate risk: LDL-C <100 mg/dL
- High risk: LDL-C <70 mg/dL
- Very high risk (prior events or advanced disease): LDL-C <55 mg/dL

For primary prevention, intervention is encouraged when LDL hits 160 mg/dL or higher in young adults without disease, especially with familial hypercholesterolemia, strong family history or elevated 30-year risk via PREVENT.

A major addition: Universal one-time lipoprotein(a) [Lp(a)] testing for all adults. This genetic marker, often inherited and underrecognized, elevates risk for heart attacks and strokes independently of LDL. Elevated Lp(a) (≥125 nmol/L or ≥50 mg/dL) prompts closer monitoring and potentially earlier therapy. Selective apolipoprotein B (ApoB) testing also gains support for refined risk assessment.

Selective coronary artery calcium (CAC) scanning is recommended for men 40+ and women 45+ with borderline/intermediate 10-year risk when statin decisions remain uncertain. Any CAC presence supports an LDL goal <100 mg/dL, with stricter targets for higher scores.

The guideline expands guidance for special populations, including children (universal screening ages 9-11), pregnant individuals, older adults and those with conditions like diabetes or chronic kidney disease. It incorporates new therapies and reinforces percent LDL reduction alongside absolute goals.

Experts hailed the updates as transformative. Dr. Roger S. Blumenthal, guideline chair and Johns Hopkins cardiologist, told reporters the approach could "cut heart attack and stroke rates down by half" through earlier, intensive prevention. "Lower LDL cholesterol for longer results in much greater protection," he said.

The shift addresses rising cardiovascular events in younger adults and underuse of proven therapies. Studies show 80% or more of cardiovascular disease is preventable, with elevated LDL a major driver. Closing treatment gaps—where many eligible patients go untreated—could avert tens of thousands of events annually, per prior analyses.

Implementation may face hurdles, including access to Lp(a) testing (widely available but not universal) and clinician adoption of new tools. Cost of earlier statins or advanced therapies concerns some, though evidence supports long-term savings via prevented events.

Patients should discuss screening with providers. A standard lipid panel (total cholesterol, HDL, LDL, triglycerides) is recommended for all adults 19+, with more frequent checks for high-risk groups. Adding Lp(a) once provides lifelong insight.

The guideline arrives amid growing awareness of metabolic risks. With cardiovascular disease still the leading U.S. killer, these evidence-based changes aim to shift focus from reactive treatment to proactive, lifetime prevention.

As adoption spreads, millions could benefit from earlier intervention, potentially reshaping heart health outcomes for generations.